Accessing our website tells us you are happy to receive all our cookies. However you can change your cookie settings at any time.

Privacy & Cookies

You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.

Alliance:

  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

Our Board of Directors

Our Board is collectively responsible for the success of the Company. As an AIM listed company the Board is committed to achieving high standards of corporate governance, integrity and business ethics.

Find out information about or Senior Leadership Team here.

David Cook Independent Non-executive Chairman

David joined the board of Alliance as a non-executive director in 2014 and was appointed Chairman of the Board on the 1 March 2018. He is currently Chief Financial Officer and an Executive Director of Ellipses Pharma, an international cancer drug development company, and was previously Chief Financial Officer and Chief Business Officer of Biotie Therapies Corp, a drug development company quoted in Helsinki and on NASDAQ. He has previously held senior financial positions with Jazz Pharmaceuticals International, EUSA Pharma and Zeneus Pharma. David qualified as a chartered accountant with PricewaterhouseCoopers after graduating in chemistry at the University of Oxford.

David has extensive experience of financial and general business management (including the implementation of buy and build strategies) in the life sciences sector, of financing those businesses and managing investor relations across a number of stock markets globally.

Peter Butterfield Chief Executive Officer

Peter was previously the company’s Deputy Chief Executive Officer and was appointed to his present office as Chief Executive Officer on the 1 May 2018 having joined Alliance in 2010 as an executive director. He served eight years as a Board Member of the Association of the British Pharmaceutical Industry and was an integral part of the 2014 PPRS negotiation team with the UK Government. Peter joined the board of Alliance in 2010 with the acquisition of Cambridge Laboratories where he spent five years, latterly as UK Commercial Director. Prior to joining Cambridge Laboratories, Peter spent six years at GlaxoSmithKline in a variety of marketing and sales roles. He holds an honours degree in Pharmacology from the University of Edinburgh.

Peter has over 20 years’ experience in the life sciences sector and strong leadership experience gained in a variety of contexts.

Andrew Franklin Chief Financial Officer

Andrew joined Alliance in September 2015 from Panasonic Europe Ltd, where he was General Manager, European Tax and Accounting. From 2010 to 2012 Andrew was Finance Director and Company Secretary of Genzyme Therapeutics Ltd, the UK & Ireland subsidiary of Genzyme Corporation. Prior to that, he gained 12 years pharmaceutical experience with Wyeth in a variety of senior financial positions. Andrew holds an honours degree in Civil Engineering from the University of Wales, Cardiff.

Andrew is a Fellow of the Institute of Chartered Accountants in England and Wales with extensive experience of financial management of international businesses, including significant prior experience in life science companies.

Nigel Clifford Independent Non-executive Director

Nigel joined the board of Alliance as a non-executive director in 2015. He was appointed Deputy Chair at the government’s new Geospatial Commission in December 2018 and is an Operating Partner with Marlin Operations Group. Previously, he held Chief Executive and senior positions at Ordnance Survey, Procserve Holdings, Micro Focus International plc, Nokia, Symbian Software, Tertio Telecoms, Cable and Wireless plc, Glasgow Royal Infirmary NHS Trust and BT plc. He also served a non-executive director of Anite plc.

Nigel graduated in Geography from the University of Cambridge and has an MBA from Strathclyde University. He brings significant experience of the strategic and commercial management of complex global businesses, gained in a variety of industry sectors and under a variety of ownership structures.

Jo LeCouilliard Independent Non-executive Director

Jo has 25 years’ healthcare management experience gained in Europe, the US and Asia. Much of her career has been in pharmaceuticals at GlaxoSmithKline where, amongst other roles, she headed the US vaccines business and Asia Pacific Pharmaceuticals business and led a program to modernise the commercial model. She was previously Chief Operating Officer at the BMI group of private hospitals in the U.K. She was non-executive director at Frimley Park NHS Foundation Trust in the UK and at the Duke NUS Medical School in Singapore.

She is currently a Non-Executive Director at UK listed companies Circassia Pharmaceuticals plc, Cello Health plc and has recently joined the board of Recordti S.p.a. Jo is a graduate of Cambridge University and a Chartered Accountant.

Richard Jones Independent Non-executive Director

Richard joined Alliance as a Non-Executive Director on 1st January 2019. Since the start of 2017 he has been CFO and a board member of Mereo BioPharma Group PLC, a UK listed biopharma company developing a range of products in bone, endocrine and respiratory therapies with a focus on rare diseases.

Richard joined Mereo from UK AIM listed Shield Therapeutics plc where he was Chief Financial Officer and Company Secretary from early 2011 having initially joined the Board as a Non-Executive Director in 2010. At Shield he had a leading role establishing the finance operations and guiding Shield through its 2016 IPO.

Prior to this, Richard had a career in investment banking, holding senior positions at Investec and Brewin Dolphin Securities, where he advised healthcare clients on a wide range of transactions and fundraisings including IPOs, M&A and fundraisings. Richard qualified as a Chartered Accountant with PwC in 1991.

Scroll to see more